EMVision Receives $10M Strategic Investment for Portable Brain Imaging

Sydney-based EMVision has announced a US$10 million strategic investment from Keysight Technologies, for clinical trials, production capacity, and commercialization of its emu™ brain scanner, a breakthrough advancement in stroke care designed to provide rapid diagnostic imaging to accelerate the delivery of urgent, life-saving care, particularly in settings where traditional imaging modalities such as CT and MRI are not readily available.

The emu™ device is operated at the point of care, with a simple cap placed on the patient’s head for quick scans and image generation. It combines safe, ultra-high frequency radio signals with powerful Artificial Intelligence to produce rapid insights directly at the patient’s bedside.

emu™ can be operated by any healthcare professional with minimal training. Targeted for use in intensive care units, stroke and neurology wards, and rural emergency departments, emu™ has the potential to improve survival rates and quality of life after stroke and other neurological events requiring urgent intervention.

The emu™️ device is neither available for sale nor evaluated by the FDA or other global regulators. The devices may only be used by authorized sites in controlled clinical investigations.